Salix Signs an Exclusive Co-Promotion Agreement for Dova’s Doptelet in the US

Salix Signs an Exclusive Co-Promotion Agreement for Dova’s Doptelet in the US

Shots:

  • Dova Pharmaceuticals to pay Salix Pharmaceuticals, a quarterly fee on the US sales. Salix to deploy ~100 specialists for promotion of Doptelet which is expected to launch in mid-Oct 2018
  • Doptelet is approved by FDA on 21 May, 2018 for thrombocytopenia in adult patients with chronic liver disease (CLD). The approval is based on P-III ADAPT-1 and ADAPT-2 trials administering 40mg or 60 mg of Doptelet vs PBO, testing safety and efficacy
  • Doptelet (avatrombopag) is once-daily orally administered, second generation TPO receptor agonist, a primary regulator of normal platelet production

Click here to read full press release/ article | Ref: Dova Pharmaceuticals  | Image: Wraltechwire